Blockade of the renin–angiotensin system has beneficial effects in patients with diabetic nephropathy; however, this treatment can induce aldosterone breakthrough and thus become ineffective. New data indicate that aldosterone breakthrough develops even when maximal doses of an angiotensin-converting-enzyme inhibitor are administered to patients with diabetic nephropathy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641–2650 (2009).
Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).
Suissa, S., Hutchinson, T., Brophy, J. M. & Kezouh, A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 69, 913–919 (2006).
Mauer, M. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40–51 (2009).
Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547–553 (2008).
Perkins, B. A., Ficociello, L. H., Roshan, B., Warram, J. H. & Krolewski, A. S. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 77, 57–64 (2010).
Kosugi, T., Heinig, M., Nakayama, T., Matsuo, S. & Nakagawa, T. eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am. J. Pathol. 176, 619–629 (2010).
Hanke, C. J. & Campbell, W. B. Endothelial cell nitric oxide inhibits aldosterone synthesis in zona glomerulosa cells: modulation by oxygen. Am. J. Physiol. Endocrinol. Metab. 279, E846–E854 (2000).
Arima, S. et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43, 352–357 (2004).
Ikeda, H. et al. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int. 75, 147–155 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Nakagawa, T. Aldosterone breakthrough in patients on an ACEI. Nat Rev Nephrol 6, 194–196 (2010). https://doi.org/10.1038/nrneph.2010.32
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.32
